Toll Free: 1-888-928-9744

Ablation Equipments - Medical Devices Pipeline Assessment, 2016

Published: Apr 15, 2016 | Pages: 95 | Publisher: GlobalData | Industry: Medical Devices | Report Format: Electronic (PDF)

Ablation Equipments - Medical Devices Pipeline Assessment, 2016

Summary

GlobalData's Medical Devices sector report, "Ablation Equipments - Medical Devices Pipeline Assessment, 2016" provides an overview of Ablation Equipments currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Ablation Equipments pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

- Extensive coverage of the Ablation Equipments under development
- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
- The report reviews the major players involved in the development of Ablation Equipments and list all their pipeline projects
- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
- The report provides key clinical trial data of ongoing trials specific to pipeline products
- Recent developments in the segment / industry

Reasons to Buy

The report enables you to - 
- Formulate significant competitor information, analysis, and insights to improve R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of Ablation Equipments under development
- Develop market-entry and market expansion strategies
- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
- In-depth analysis of the product's current stage of development, territory and estimated launch date
 Table of Contents
Table of Contents 2 1.1 List of Tables 5 1.2 List of Figures 7 2 Introduction 8 2.1 Ablation Equipments Overview 8 3 Products under Development 9 3.1 Ablation Equipments - Pipeline Products by Stage of Development 9 3.2 Ablation Equipments - Pipeline Products by Territory 10 3.3 Ablation Equipments - Pipeline Products by Regulatory Path 11 3.4 Ablation Equipments - Pipeline Products by Estimated Approval Date 12 3.5 Ablation Equipments - Ongoing Clinical Trials 13 4 Ablation Equipments - Pipeline Products under Development by Companies 14 4.1 Ablation Equipments Companies - Pipeline Products by Stage of Development 14 4.2 Ablation Equipments - Pipeline Products by Stage of Development 15 5 Ablation Equipments Companies and Product Overview 16 5.1 AngioDynamics, Inc. Company Overview 16 5.1.1 AngioDynamics, Inc. Pipeline Products & Ongoing Clinical Trials Overview 16 5.2 AtriCure, Inc. Company Overview 27 5.2.1 AtriCure, Inc. Pipeline Products & Ongoing Clinical Trials Overview 27 5.3 CPSI Biotech Company Overview 29 5.3.1 CPSI Biotech Pipeline Products & Ongoing Clinical Trials Overview 29 5.4 EP Global Communications, Inc. Company Overview 31 5.4.1 EP Global Communications, Inc. Pipeline Products & Ongoing Clinical Trials Overview 31 5.5 HistoSonics, Inc. Company Overview 33 5.5.1 HistoSonics, Inc. Pipeline Products & Ongoing Clinical Trials Overview 33 5.6 Hospital for Special Surgery Company Overview 36 5.6.1 Hospital for Special Surgery Pipeline Products & Ongoing Clinical Trials Overview 36 5.7 Innoblative Designs, Inc. Company Overview 37 5.7.1 Innoblative Designs, Inc. Pipeline Products & Ongoing Clinical Trials Overview 37 5.8 Integra LifeSciences Holdings Corporation Company Overview 40 5.8.1 Integra LifeSciences Holdings Corporation Pipeline Products & Ongoing Clinical Trials Overview 40 5.9 Intratherm, Llc Company Overview 42 5.9.1 Intratherm, Llc Pipeline Products & Ongoing Clinical Trials Overview 42 5.10 Medtronic plc Company Overview 43 5.10.1 Medtronic plc Pipeline Products & Ongoing Clinical Trials Overview 43 5.11 Memorial Sloan Kettering Cancer Center Company Overview 51 5.11.1 Memorial Sloan Kettering Cancer Center Pipeline Products & Ongoing Clinical Trials Overview 51 5.12 Mirabilis Medical, Inc. Company Overview 53 5.12.1 Mirabilis Medical, Inc. Pipeline Products & Ongoing Clinical Trials Overview 53 5.13 Prosurg, Inc. Company Overview 55 5.13.1 Prosurg, Inc. Pipeline Products & Ongoing Clinical Trials Overview 55 5.14 Smith & Nephew Plc Company Overview 57 5.14.1 Smith & Nephew Plc Pipeline Products & Ongoing Clinical Trials Overview 57 5.15 Thermedical, Inc. Company Overview 59 5.15.1 Thermedical, Inc. Pipeline Products & Ongoing Clinical Trials Overview 59 5.16 TransEnterix, Inc. Company Overview 61 5.16.1 TransEnterix, Inc. Pipeline Products & Ongoing Clinical Trials Overview 61 5.17 University of California, San Francisco Company Overview 62 5.17.1 University of California, San Francisco Pipeline Products & Ongoing Clinical Trials Overview 62 5.18 University of Texas at Austin Company Overview 63 5.18.1 University of Texas at Austin Pipeline Products & Ongoing Clinical Trials Overview 63 5.19 University of Wisconsin-Stout Company Overview 64 5.19.1 University of Wisconsin-Stout Pipeline Products & Ongoing Clinical Trials Overview 64 6 Ablation Equipments- Recent Developments 66 6.1 Mar 22, 2016: Kim Bridges joins Halt Medical as President and Chief Executive Officer 66 6.2 Mar 21, 2016: CSA Medical Announces the First Presentation of the RejuvenAir System Metered Cryospray Clinical Data 66 6.3 Feb 25, 2016: Integra LifeSciences Reports Fourth Quarter and Full Year 2015 Financial Results and Issues 2016 Full Year Guidance 67 6.4 Feb 25, 2016: Integra LifeSciences Announces Service Alliance Agreement With PREZIO Health 68 6.5 Feb 09, 2016: Misonix Announces Second Quarter Fiscal Year 2016 Financial Results 69 6.6 Jan 13, 2016: Medtronic Expands Pain Therapies Portfolio with the Launch of OsteoCool RF Ablation System 70 6.7 Dec 22, 2015: Galil Medical Terminates Acquisition of Perseon for up to USD10.6 Million 71 6.8 Dec 18, 2015: Relievant Medsystems Raises USD1.5 Million in Venture Financing 71 6.9 Dec 16, 2015: Medtronic Acquires OsteoCool RF Ablation System from Baylis Medical 71 6.10 Dec 15, 2015: DFINE Announces Commercial Launch of the Long SpineSTAR Ablation Instrument for the Palliative Treatment of Metastatic Spine Tumors 71 6.11 Nov 26, 2015: Google Files For Patent For Laser Ablation Surgical System 72 6.12 Nov 10, 2015: C2 Therapeutics Announces New Data Confirming Efficacy and Safety of Coldplay CryoBalloon Focal Ablation System to Treat Esophageal Disease 72 6.13 Nov 05, 2015: Misonix Announces First Quarter Fiscal Year 2016 Financial Results 73 6.14 Nov 03, 2015: Integra LifeSciences Reports Third Quarter 2015 Financial Results 74 6.15 Oct 30, 2015: Integra LifeSciences Receives Expanded Indication for CUSA Excel+ System for Liver Surgery 75 6.16 Oct 15, 2015: AngioDynamics Announces the Approval of the NanoKnife System in South Korea 75 6.17 Sep 15, 2015: Perseon Announces New Data for MicroThermX in the Treatment of Large Liver Metastases From Colorectal Cancer and Large Hepatocellular Carcinoma From 2015 SICO Conference 76 6.18 Aug 31, 2015: Perseon Announces the Initiation of the First Multi-Organ in vivo Ablation Zone Study for MicroThermX in Laparoscopic and Open Approaches 76 6.19 Aug 31, 2015: Integra LifeSciences Raises USD220 Million in Public Offering of Shares 77 6.20 Aug 20, 2015: Misonix Announces Fourth Quarter And Fiscal Year End 2015 Financial Results 77 6.21 Aug 19, 2015: Perseon Launches INSPIRE 2017, a Dramatic Effort to Increase Adoption of Microwave Ablation to Fight Cancer 79 6.22 Aug 13, 2015: Research Data Published in Annals of Surgery Concludes Irreversible Electroporation Utilizing NanoKnife Results in Substantially Prolonged Survival for Patients With Locally Advanced Pancreatic Cancer Compared With Historical Controls 80 6.23 Aug 06, 2015: Perseon Announces Data Presented at the American Association of Physicists in Medicine Meeting Supporting the Use of Microwave Ablation 80 6.24 Aug 04, 2015: Perseon Announces a User Enhancement Upgrade for Energy Ablation System MicroThermX 81 6.25 Aug 04, 2015: Integra LifeSciences Prices Public Offering of Shares for USD201.3 Million 81 6.26 Jul 30, 2015: Integra LifeSciences Reports Second Quarter 2015 Financial Results 82 6.27 Jul 29, 2015: C2 Therapeutics Receives FDA 510(k) Clearance for the Coldplay Full CryoBalloon Ablation System 83 6.28 Jul 29, 2015: C2 Therapeutics Receives FDA 510(k) Clearance for the Coldplay Swipe CryoBalloon Ablation System 83 6.29 Jul 20, 2015: C2 Therapeutics Announces Successful Safety and Dosing Results of Coldplay Cryoballoon Focal Ablation System in International Trial 83 6.30 Jul 16, 2015: Cianna Medical Raises USD4 Million in Venture Financing Round 84 6.31 Jul 09, 2015: SonaCare Medical Sells Prostate Ablation System with MRI/Ultrasound Image Fusion to Heidelberg Prostate Clinic 84 6.32 Jul 01, 2015: Integra LifeSciences Completes Spin-Off of SeaSpine 85 6.33 May 18, 2015: CSA Medical Announces Publication of Results of National Cryospray Registry in Diseases of the Esophagus 85 6.34 May 07, 2015: Misonix Announces Third Quarter Fiscal Year 2015 Financial Results 86 6.35 May 06, 2015: Perseon's MicroThermX to be Featured at WCIO 2015 Interventional Oncology Forum 87 6.36 May 06, 2015: NeuWave Medical Raises USD25 Million in Series C Financing 87 6.37 Apr 30, 2015: Integra LifeSciences Names Keith Valentine as Chief Executive Officer of SeaSpine; John Bostjancic Appointed as Chief Financial Officer of SeaSpine 88 6.38 Apr 30, 2015: Integra LifeSciences Reports First Quarter 2015 Financial Results 88 6.39 Apr 24, 2015: New Data Shows Irreversible Electroporation Nearly Doubles Overall Survival of Patients with Locally Advanced Pancreatic Cancer When Added to Standard Therapy 90 6.40 Apr 14, 2015: Perseon Announces FDA Clearance for Specific Indication of Non-Resectable Liver Tumor Ablation 91 7 Appendix 92 7.1 Methodology 92 7.2 About GlobalData 94 7.3 Contact Us 95 7.4 Disclaimer 95
List of Tables
Table 1: Ablation Equipments - Pipeline Products by Stage of Development 9 Table 2: Ablation Equipments - Pipeline Products by Territory 10 Table 3: Ablation Equipments - Pipeline Products by Regulatory Path 11 Table 4: Ablation Equipments - Pipeline Products by Estimated Approval Date 12 Table 5: Ablation Equipments - Ongoing Clinical Trials 13 Table 6: Ablation Equipments Companies - Pipeline Products by Stage of Development 14 Table 7: Ablation Equipments - Pipeline Products by Stage of Development 15 Table 8: AngioDynamics, Inc. Pipeline Products & Ongoing Clinical Trials Overview 16 Table 9: NanoKnife Low Energy Direct Current System - Hepatocellular Carcinoma - Product Status 17 Table 10: NanoKnife Low Energy Direct Current System - Hepatocellular Carcinoma - Product Description 17 Table 11: NanoKnife System - Pancreatic Cancer - Product Status 18 Table 12: NanoKnife System - Pancreatic Cancer - Product Description 18 Table 13: NanoKnife System - Prostate Cancer - Product Status 19 Table 14: NanoKnife System - Prostate Cancer - Product Description 19 Table 15: Next Generation Microwave Ablation - Product Status 20 Table 16: Next Generation Microwave Ablation - Product Description 20 Table 17: Next Generation NanoKnife Device - Product Status 21 Table 18: Next Generation NanoKnife Device - Product Description 21 Table 19: AngioDynamics, Inc. - Ongoing Clinical Trials Overview 22 Table 20: NanoKnife System - Prostate Cancer - A Prospective Development Study Evaluating Focal Therapy Using Irreversible Electroporation (Nanoknife) in Men with Localised Prostate Cancer 23 Table 21: NanoKnife System - Prostate Cancer - Irreversible Electroporation(IRE) for Unresectable Prostatic Neoplasms: Phase I and Phase II Clinical Trial 23 Table 22: NanoKnife System - Prostate Cancer - Multi-center Randomized Clinical Two Arm Intervention Study Evaluating Irreversible Electroporation for the Ablation of Localized Prostate Cancer 23 Table 23: NanoKnife System - Pancreatic Cancer - Evaluation of the Short and Intermediate Term Outcomes of Ablation of Locally Advanced Unresectable Pancreatic Cancer Using the NanoKnife Irreversible Electroporation (IRE) System - A Prospective Study 24 Table 24: NanoKnife System - Pancreatic Cancer - IRE: Anti-tumor Immunity Induced by IRE of Unresectable Pancreatic Cancer 24 Table 25: NanoKnife Low Energy Direct Current System - Hepatocellular Carcinoma - A Prospective Clinical Trial Using Irreversible Electroporation (IRE) for the Treatment of Unresectable Hepatic Carcinoma Close to the Gallbladder 25 Table 26: NanoKnife Low Energy Direct Current System - Hepatocellular Carcinoma - Colorectal Metastatic Liver Disease: Efficacy of Irreversible Electroporation (IRE) - A Phase II Clinical Trial (COLDFIRE-2 Study) 25 Table 27: NanoKnife Low Energy Direct Current System - Hepatocellular Carcinoma - Comparison Percutaneous Cryosurgery and Irreversible Electroportion in Unresectable Liver Cancer Close to Diaphragmatic Dome 26 Table 28: NanoKnife Low Energy Direct Current System - Hepatocellular Carcinoma - Hepatic Carcinoma in Poor Liver Function: Safety and Efficacy of Irreversible Electroporation (IRE) 26 Table 29: NanoKnife Low Energy Direct Current System - Hepatocellular Carcinoma - Irreversible Electroporation (IRE) for Unresectable Portal Venous Tumor Emboli: Phase I and Phase II Clinical Trial 26 Table 30: AtriCure, Inc. Pipeline Products & Ongoing Clinical Trials Overview 27 Table 31: COBRA Revolution Bipolar Clamp - Product Status 28 Table 32: COBRA Revolution Bipolar Clamp - Product Description 28 Table 33: CPSI Biotech Pipeline Products & Ongoing Clinical Trials Overview 29 Table 34: Pressurized Sub-Cooled Nitrogen System - Product Status 29 Table 35: Pressurized Sub-Cooled Nitrogen System - Product Description 29 Table 36: Super-Critical Nitrogen (SCN) Cryoablation Platform - Product Status 30 Table 37: Super-Critical Nitrogen (SCN) Cryoablation Platform - Product Description 30 Table 38: EP Global Communications, Inc. Pipeline Products & Ongoing Clinical Trials Overview 31 Table 39: MEMS Nerve Ablation Device - Back Pain - Product Status 31 Table 40: MEMS Nerve Ablation Device - Back Pain - Product Description 31 Table 41: MEMS Nerve Ablation Device - Facial Glabballar Frowning - Product Status 32 Table 42: MEMS Nerve Ablation Device - Facial Glabballar Frowning - Product Description 32 Table 43: HistoSonics, Inc. Pipeline Products & Ongoing Clinical Trials Overview 33 Table 44: Vortx RX - Product Status 33 Table 45: Vortx RX - Product Description 33 Table 46: HistoSonics, Inc. - Ongoing Clinical Trials Overview 34 Table 47: Vortx RX - Safety and Initial Efficacy Study of the Vortx Rx for Treatment of Benign Prostatic Hyperplasia (US) 35 Table 48: Hospital for Special Surgery Pipeline Products & Ongoing Clinical Trials Overview 36 Table 49: Radiofrequency Ablation Device - Product Status 36 Table 50: Radiofrequency Ablation Device - Product Description 36 Table 51: Innoblative Designs, Inc. Pipeline Products & Ongoing Clinical Trials Overview 37 Table 52: RFA Applicator - Product Status 37 Table 53: RFA Applicator - Product Description 37 Table 54: Innoblative Designs, Inc. - Ongoing Clinical Trials Overview 38 Table 55: RFA Applicator - Feasibility Study of Cavitary Radiofrequency Ablation in Excised Mastectomy Breast Tissue 39 Table 56: Integra LifeSciences Holdings Corporation Pipeline Products & Ongoing Clinical Trials Overview 40 Table 57: CUSA Ultrasonic Tissue Ablation System - Liver - Product Status 41 Table 58: CUSA Ultrasonic Tissue Ablation System - Liver - Product Description 41 Table 59: Intratherm, Llc Pipeline Products & Ongoing Clinical Trials Overview 42 Table 60: CITT Device - Product Status 42 Table 61: CITT Device - Product Description 42 Table 62: Medtronic plc Pipeline Products & Ongoing Clinical Trials Overview 43 Table 63: Barrx 360 Express - Product Status 44 Table 64: Barrx 360 Express - Product Description 44 Table 65: Electrosurgical Ablation Device - Product Status 45 Table 66: Electrosurgical Ablation Device - Product Description 45 Table 67: Nerve Cryoablation System - Product Status 46 Table 68: Nerve Cryoablation System - Product Description 46 Table 69: OsteoCool V-2 RF Ablation System - Product Status 47 Table 70: OsteoCool V-2 RF Ablation System - Product Description 47 Table 71: Phased RF Ablation System - Product Status 48 Table 72: Phased RF Ablation System - Product Description 48 Table 73: Medtronic plc - Ongoing Clinical Trials Overview 49 Table 74: Phased RF Ablation System - Evaluation of Multielectrode Phased RF Technology in Persistent Atrial Fibrillation 50 Table 75: Memorial Sloan Kettering Cancer Center Pipeline Products & Ongoing Clinical Trials Overview 51 Table 76: Image-Guided Ablation Device - Product Status 52 Table 77: Image-Guided Ablation Device - Product Description 52 Table 78: Mirabilis Medical, Inc. Pipeline Products & Ongoing Clinical Trials Overview 53 Table 79: Mirabilis System - Product Status 54 Table 80: Mirabilis System - Product Description 54 Table 81: Prosurg, Inc. Pipeline Products & Ongoing Clinical Trials Overview 55 Table 82: ImaGel - Product Status 56 Table 83: ImaGel - Product Description 56 Table 84: Smith & Nephew Plc Pipeline Products & Ongoing Clinical Trials Overview 57 Table 85: Next-Generation COBLATION Platform - Product Status 58 Table 86: Next-Generation COBLATION Platform - Product Description 58 Table 87: Thermedical, Inc. Pipeline Products & Ongoing Clinical Trials Overview 59 Table 88: SERF Ablation System - Fibroids - Product Status 60 Table 89: SERF Ablation System - Fibroids - Product Description 60 Table 90: TransEnterix, Inc. Pipeline Products & Ongoing Clinical Trials Overview 61 Table 91: Barrett's Excision Device - Product Status 61 Table 92: Barrett's Excision Device - Product Description 61 Table 93: University of California, San Francisco Pipeline Products & Ongoing Clinical Trials Overview 62 Table 94: Robotic Needle Ablation Tool And Securement Device - Product Status 62 Table 95: Robotic Needle Ablation Tool And Securement Device - Product Description 62 Table 96: University of Texas at Austin Pipeline Products & Ongoing Clinical Trials Overview 63 Table 97: Plasmonic Laser Ablation Device - Product Status 63 Table 98: Plasmonic Laser Ablation Device - Product Description 63 Table 99: University of Wisconsin-Stout Pipeline Products & Ongoing Clinical Trials Overview 64 Table 100: Microwave Ablation Probe - Product Status 65 Table 101: Microwave Ablation Probe - Product Description 65 Table 102: Glossary 93


List of Figures
Figure 1: Ablation Equipments - Pipeline Products by Stage of Development 9 Figure 2: Ablation Equipments - Pipeline Products by Territory 10 Figure 3: Ablation Equipments - Pipeline Products by Regulatory Path 11 Figure 4: Ablation Equipments - Pipeline Products by Estimated Approval Date 12 Figure 5: Ablation Equipments - Ongoing Clinical Trials 13

To request a free sample copy of this report, please complete the form below.

This website is secure and your personal details are safe. Privacy policy

Global agricultural films market size is anticipated to reach USD 10.5 billion by 2020, as per a new research report by Radiant Insights, Inc. Increasing need to raise agricultural productivity, in order to meet surplus demand by growing population i

Read More...

Global contact lenses market size is estimated to reach USD 12.5 billion by 2020, according to a new industry report by Radiant Insights, Inc. Growing number of ophthalmic disorder observed in global population especially children is likely to drive

Read More...

Global Automated Test Equipment (ATE) market is expected to be valued at USD 4.48 billion by 2020, as per a new research report by Radiant Insights, Inc. Increasing design complexity coupled with need for effective testing is expected to drive the gl

Read More...

Global animal feed additives market size was estimated at USD 16 billion in 2014. Growing meat consumption as a key protein source, especially in Asia Pacific and Latin America is expected to be a key driver for market demand over the forecast period

Read More...

Global gas sensors market is expected to reach USD 2,512.4 million by 2020, as per a new research report by Radiant Insights, Inc. High adoption rate of wireless and smart gas sensor technology coupled with escalating demand from end-use industries s

Read More...
Choose License Type
Single User - US $2500
Multi User - US $5000
Why Choose Us

24/5 Research support

Get your queries resolved from an industry expert. Request for a free product review before report purchase.

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.

verify